CN1520824A - Pharmaceutical use of asiaticoside - Google Patents
Pharmaceutical use of asiaticoside Download PDFInfo
- Publication number
- CN1520824A CN1520824A CNA03115199XA CN03115199A CN1520824A CN 1520824 A CN1520824 A CN 1520824A CN A03115199X A CNA03115199X A CN A03115199XA CN 03115199 A CN03115199 A CN 03115199A CN 1520824 A CN1520824 A CN 1520824A
- Authority
- CN
- China
- Prior art keywords
- asiaticoside
- liver
- group
- fibrosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The present invention discloses the use of asiaticoside in preparing medicine for treating liver fibrillation. Asiaticoside can suppress the growth and proliferation of fibroblast obviously, so that it may be used in treating liver fibrillation and further in preventing hepatocirrhosis.
Description
Technical field
The present invention relates to the medicinal usage of Asiaticoside, particularly relate to the purposes that its preparation prevents hepatic fibrosis medicines.
Background technology
Asiaticoside is a kind of known substance, and it is the representative composition in the Total Of Triterpenes (a kind of active drug composition that extracts from the samphire Herba Centellae mainly contains the triterpenoid saponin compounds), and it belongs to pentacyclic triterpenoid.The molecular formula of Asiaticoside is C
48H
78O
19, this material is a kind of, is slightly soluble in water, methanol, alcoholic acid tiny acicular crystal.The known drugs purposes of Total Of Triterpenes is the medicine with its preparation treatment scleroderma and treatment wound, operation wound and burn.And the medicinal usage of Asiaticoside is not reported so far.
The applicant is by long-term deep discovering, contained Asiaticoside has the effect that fibrocyte is grown up and bred that is suppressed in the Total Of Triterpenes.As everyone knows, hepatic fibrosis is the cercinoma prophase pathologic change of liver cirrhosis, is that a variety of causes causes the pathological change that chronic hepatic injury is common.The development of hepatic fibrosis will cause liver cirrhosis.Therefore blocking-up inhibition or reverse hepatic fibrosis are crucial means of treatment chronic hepatopathy.Suppress liver growth of fibroblasts propagation and will prevent hepatic fibrosis, thereby can prevent liver cirrhosis.Utilize the effect that is suppressed to fibroblast growth propagation of Asiaticoside, a kind of new drug for the treatment of liver cirrhosis might be provided.
Summary of the invention
The object of the present invention is to provide the Asiaticoside preparation to suppress the medicinal usage of hepatic fibrosis.
The applicant is by the preventive and therapeutic effect of research Asiaticoside to the rat liver fibrosis of N-nitrosodimethylamine initiation, confirmed that Asiaticoside has the function that is suppressed to fibroblast growth propagation, and then determined purposes with the preparation treatment hepatic fibrosis medicines of Asiaticoside.
Specifically describe the present invention below by embodiment.
Concrete embodiment
Embodiment 1
Adult SD rats with health experimentizes.Described SD rat is divided into: 1,2,3 and 4 group of normal control group, Asiaticoside treatment, and Liver Fibrosis Model group.Wherein:
1) the normal control group is got 10 of described SD rats, carries out saline lumbar injection, distilled water filling stomach;
2) Liver Fibrosis Model group, get 10 of described SD rats, it is carried out lumbar injection, 0.5% the N-nitrosodimethylamine solution that is made into normal saline 12 times, dosage is 10mg N-nitrosodimethylamine/kg body weight/time (N-nitrosodimethylamine/kg body weight of 2ml0.5%/time), be to inject 3 days continuously by the frequency of injecting 1 every day in the 1st cycle inject time, injects altogether 3 times; Inject totally 3 times 2-4 week weekly 1 time; 5-7 week injects 1 time frequency every day and injects, totally 6 times by continuous 2 days weekly.Amount to every SD rat injection 0.5% N-nitrosodimethylamine solution totally 12 times, to set up Liver Fibrosis Model.Rat freely drinks water and ingests during injecting.
3) the Asiaticoside treatment is respectively got 10 of described SD rats for 1,2,3 and 4 group, injects 0.5% N-nitrosodimethylamine solution by the mode of Liver Fibrosis Model group.3 weeks treated with Asiaticoside after modelling, and the dosage of 1-4 group is respectively: 1.5mg Asiaticoside/kg body weight/sky, 3.0mg Asiaticoside/kg body weight/sky, 6.0mg Asiaticoside/kg body weight/sky and 12mg Asiaticoside/kg body weight/sky.
Used Asiaticoside is provided by Haitian Medicine Science and Technology Development Co., Ltd., Shanghai in the above-mentioned 1-4 treatment group, and lot number is 20010908.Described Asiaticoside is made into the solution of respective concentration by distilled water, and with the dosage of 10ml solution/kg body weight, distilled water is irritated the mode administration of stomach.The treatment persistent period is 8 days.
After experiment finished, the sodium pentobarbital normal saline solution with 3% carries out lumbar injection (45mg sodium pentobarbital/kg body weight) to experimental rat made its anesthesia, prepares serum from abdominal aortic blood, preserved to be measured in-30 ℃ of refrigerators.Get liver after the blood sampling and weigh, and get the lobus sinister liver and place 10% formalin solution fixing, simultaneously by electron microscopy observation requirement making liver specimen to carry out histopathology observation.
Press George J, Rao K R, Stem R, Chandrankasan G.Dimethylnigrosamine-induced liver injury in rats:the earlydesposition.Toxicoloy, 2001; 156 (2): the mode described in the 129-138 is observed described rat liver tissue inflammation mobility (G) (0-4 level);
Viral liver class by the 5th national infectious disease parasitic disease academic conference discussion revision is prevented and treated scheme (trying) (CHINESE JOURNAL OF INTERNAL MEDICINE, 1995; 34 (11): 788-791) described method is observed described liver tissues of rats fibrosis (s) (0-4 phase)
Observed result sees the following form
The Asiaticoside preparation is to the influence by stages of rat liver fibrosis pathological grading
The liver fibrillation by stages of group inflammation classification fibrosis
N 0123401234 incidence rates (%)
Normal group 10 91000 10 00000
Model group 10 0622012331 90
Asiaticoside group 1 10 0820053110 50
Asiaticoside group 2 10 0901063010 40
Asiaticoside group 3 10 0730072010 30
Asiaticoside group 4 10 3520072100 30
From the observed result shown in the last table as can be known, Asiaticoside has good preventive and therapeutic effect for hepatic fibrosis, and when dosage was 6-250mg Asiaticoside/sky, this preventive and therapeutic effect was particularly evident.
Claims (1)
1, the purposes of Asiaticoside preparation treatment hepatic fibrosis medicines
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03115199 CN1264518C (en) | 2003-01-27 | 2003-01-27 | Pharmaceutical use of asiaticoside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03115199 CN1264518C (en) | 2003-01-27 | 2003-01-27 | Pharmaceutical use of asiaticoside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1520824A true CN1520824A (en) | 2004-08-18 |
| CN1264518C CN1264518C (en) | 2006-07-19 |
Family
ID=34284172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03115199 Expired - Fee Related CN1264518C (en) | 2003-01-27 | 2003-01-27 | Pharmaceutical use of asiaticoside |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1264518C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032502B (en) * | 2006-03-06 | 2011-10-05 | 上海医药工业研究院 | Application of centella triterpenes in the preparing of medicine for preventing and curing pancreatic fibrosis |
| WO2011154966A1 (en) | 2010-06-10 | 2011-12-15 | Indus Biotech Pvt. Ltd. | A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof |
-
2003
- 2003-01-27 CN CN 03115199 patent/CN1264518C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032502B (en) * | 2006-03-06 | 2011-10-05 | 上海医药工业研究院 | Application of centella triterpenes in the preparing of medicine for preventing and curing pancreatic fibrosis |
| WO2011154966A1 (en) | 2010-06-10 | 2011-12-15 | Indus Biotech Pvt. Ltd. | A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof |
| US9139608B2 (en) | 2010-06-10 | 2015-09-22 | Indus Biotech Private Limited | Method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1264518C (en) | 2006-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7901707B2 (en) | Biodegradable biocompatible implant and method of manufacturing same | |
| TW200936167A (en) | Non-polymeric compositions for controlled drug delivery | |
| TW200418495A (en) | Use of CCI-779 in treatment of hepatic fibrosis | |
| US20230355837A1 (en) | Berberine/mineralized collagen-based composite membrane and preparation method and application thereof | |
| US20220031618A1 (en) | Irinotecan liposome preparation, and preparation and application thereof | |
| CN101095668B (en) | Application of rosmarinic acid in the preparation of medicines for treating or preventing liver fibrosis and kidney fibrosis | |
| WO2007042010A2 (en) | Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids | |
| AU2009233594A1 (en) | Injectable preparations of diclofenac and its pharmaceutically acceptable salts | |
| CN1264518C (en) | Pharmaceutical use of asiaticoside | |
| CN102258516A (en) | Application of 13-methylamino-18-sulfo matrine compound in preparing medicines for resisting liver fibrosis or fibrosis of other tissues and organs | |
| AU2013377404B2 (en) | Composition of cabazitaxel and sulfobutylether beta-cyclodextrin | |
| EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
| CN114831939A (en) | Triamcinolone acetonide acetate composition spray and preparation method thereof | |
| US6197818B1 (en) | Drug for treating diabetic nephrosis | |
| CN1164269C (en) | Silybin injection containing cyclo dextrin or its derivatives | |
| CN114984005B (en) | Application of sulbactam sodium sulfate in preparation of medicines for resisting renal failure | |
| DE4244265C2 (en) | Use of Paf antagonists against the new formation of Paf binding sites on endothelial cells for the treatment or prevention of hyperinsulinism | |
| US20240148686A1 (en) | Pharmaceutical composition of forskolin-isoforskolin and pentacyclic triterpenoid compound, and application thereof | |
| CN102846760A (en) | Preparation process of integration-type novel formulation of Cinnamomum cassia and Poria cocos decoction and production method thereof. | |
| CN108721214B (en) | Netupidan and palonosetron compound nanoparticle solution, nanoparticles, preparation method and application | |
| CN1526389A (en) | Application of 5,7,4'-substituted flavone in preparing medicine | |
| IT9022342A1 (en) | FORMULATIONS OF LYOPHILIZED AMINO ACIDS CONTAINING GLUTAMINE, THEIR PREPARATION AND USE IN THE PARENTERAL FEEDING | |
| CN104623676B (en) | A kind of pharmaceutical composition for preventing and treating chronic hepatitis B and its application | |
| SURİYAPRAKASH et al. | Formulation and evaluation of paclitaxel niosome for its improved anti-cancer activity | |
| CN104958255A (en) | Flumazenil injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060719 Termination date: 20170127 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |